TITLE

Aminoglycoside Toxicity: Daily versus Thrice-Weekly Dosing for Treatment of Mycobacterial Diseases

AUTHOR(S)
Peloquin, Charles A.; Berning, Shaun E.; Nitta, Annette T.; Simone, Patricia M.; Goble, Marian; Huitt, Gwen A.; Lseman, Michael D.; Cook, James L.; Curran-Everetf, Douglas
PUB. DATE
June 2004
SOURCE
Clinical Infectious Diseases;6/1/2004, Vol. 38 Issue 11, p1538
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Aminoglycoside use is limited by ototoxicity and nephrotoxicity. This study compared the incidences of toxicities associated with 2 recommended dosing regimens. Eighty-seven patients with tuberculosis or non-tuberculous mycobacterial infections were prospectively randomized by drug to receive 15 mg/kg per day or 25 mg/kg 3 times per week of intravenous streptomycin, kanamycin, or amikacin. Doses were adjusted to achieve target serum concentrations. The size of the dosage and the frequency of administration were not associated with the incidences of ototoxicity (hearing loss determined by audiogram), vestibular toxicity (determined by the findings of a physical examination), or nephrotoxicity (determined by elevated serum creatinine levels). Risk of ototoxicity (found in 32 [37%] of the patients) was associated with older age and with a larger cumulative dose received. Vestibular toxicity (found in 8 [9%I of the patients) usually resolved, and nephrotoxicity (found in 13 [15%I of the patients) was mild and reversible in all cases. Subjective changes in hearing or balance did not correlate with objective findings. Streptomycin, kanamycin, and amikacin can be administered either daily or 3 times weekly without affecting the likelihood of toxicity.
ACCESSION #
13239011

 

Related Articles

  • Proteomic analysis of streptomycin resistant and sensitive clinical isolates of Mycobacterium tuberculosis. Sharma, Prashant; Kumar, Bhavnesh; Gupta, Yash; Singhal, Neelja; Katoch, Vishwa Mohan; Venkatesan, Krishnamurthy; Bisht, Deepa // Proteome Science;2010, Vol. 8, p59 

    Background: Streptomycin (SM) is a broad spectrum antibiotic and is an important component of any antituberculosis therapy regimen. Several mechanisms have been proposed to explain the emergence of resistance but still our knowledge is inadequate. Proteins form a very complex network and drugs...

  • Risk Factors for Nephrotoxicity in Patients Treated with Aminoglycosides. Moore, Richard D.; Smith, Craig R.; Lipsky, James J.; Mellits, David; Lietman, Paul S. // Annals of Internal Medicine;Mar84, Vol. 100 Issue 3, p352 

    Presents information on a study which determined risk factors for nephrotoxicity in patients treated with aminoglycosides. Methods; Results; Discussion.

  • Aminoglycosides: A practical review. Gonzalez III, Luis S.; Spencer, Jeanne P. // American Family Physician;11/15/1998, Vol. 58 Issue 8, p1811 

    Focuses on aminoglycosides, the potent bactericidal antibiotics that act by creating fissures in the outer membrane of the bacterial cell. Pharmacology; Clinical uses; Drug interactions and adverse effects.

  • Evaluating once daily dosing of aminoglycosides: An... Okpara, Alphonsus U.; Amaya-Diaz, Analiza // Formulary;Jan1996, Vol. 31 Issue 1, p34 

    Presents results of an observational report on 107 patients to evaluate the clinical efficacy and nephrotoxicity associated with once daily dosing of aminoglycoside. Definition of aminoglycosides; Clinical response of patients. INSETS: Criteria used to define clinical responses to...

  • Once-daily aminoglycoside dosing: Impact on requests and costs for therapeutic drug monitoring. Crane, John K. // Cortlandt Forum;06/25/97, Vol. 10 Issue 6, p31 

    Presents results of a study in which once-daily aminoglycoside dosing for adult patients were conducted. Therapeutic drug monitoring; Nephrotoxicity; Comment on the absence of rationale for checking peak drug levels.

  • In Vitro Efficacy of Fusidic Acid on Drug Resistant Strains of Mycobacterium Tuberculosis. Öztaş, Selahattin; Kurutepe, Melahat; Adıgüzel, Nalan; Acartürk, Eylem; Saraç, Sema; Maraşlı, Dida; Tümer, Özlen; Hazar, Armağan // Turk Toraks Dergisi / Turkish Thoracic Journal;Sep2008, Vol. 9 Issue 3, p109 

    Introduction: We aimed to investigate the in vitro efficacy of fusidic acid (FA) on tuberculosis strains resistant to antituberculous drugs . Material and Method: In our single center, prospective, randomized controlled study, we researched the efficacy of sodium fucidate on tuberculosis bacilli...

  • Aminoglycoside supplementation of TB therapy. Gettler, James // Cortlandt Forum;2/25/95, Vol. 8 Issue 2, p42 

    Presents a query on aminoglycoside indication in cases of cavitary tuberculosis. Drug penetration of the cavities; Recommended dosage; Complications from long-term use of aminoglycoside.

  • Etimicin.  // Reactions Weekly;9/15/2012, Issue 1419, p20 

    The article describes the case of a 45-year-old man who experienced paradoxical deterioration of cervical tuberculous lymphadenitis while undergoing etimicin therapy.

  • Advances in the treatment of pulmonary tuberculosis. Xia Zhang; Jing Guo // Journal of Thoracic Disease;Dec2012, Vol. 4 Issue 6, p617 

    The article focuses on the developments in the treatment of pulmonary tuberculosis (PTB). It states that interventional therapy is a latest therapeutic approach for PTB including bronchoscopy, bronchial artery embolization and pulmonary artery embolization. It further states that...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics